Armata Pharmaceuticals Management

Management criteria checks 1/4

Armata Pharmaceuticals' CEO is Deborah Birx, appointed in Jul 2023, has a tenure of less than a year. directly owns 0.72% of the company’s shares, worth $663.11K. The average tenure of the management team and the board of directors is 0.8 years and 4.3 years respectively.

Key information

Deborah Birx

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.7%
Management average tenure	less than a year
Board average tenure	4.3yrs

Recent management updates

Recent updates

CEO

Deborah Birx (66 yo)

less than a year

Tenure

Dr. Deborah L. Birx, M.D., serves as CEO & Director of Armata Pharmaceuticals, Inc. since July 11, 2023. He is Member of Palantir Federal Advisory Board at Palantir Technologies Inc. since October 2022. Sh...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Mina Pastagia	Chief Medical Officer	3.6yrs	US$839.24k	0.12% $ 110.5k
Deborah Birx	CEO & Director	less than a year	no data	0.72% $ 663.1k
Richard Rychlik	VP, Corporate Controller & Principal Financial Officer	less than a year	no data	0.028% $ 25.5k
Peter Hubbard	Vice President of Operations	less than a year	no data	no data
Pierre Kyme	Senior Vice President of Business & Corporate Development	less than a year	no data	no data

0.8yrs

Average Tenure

66yo

Average Age

Experienced Management: ARMP's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Deborah Birx	CEO & Director	less than a year	no data	0.72% $ 663.1k
Joseph Patti	Independent Director	5yrs	US$177.11k	0% $ 0
Jules Haimovitz	Independent Director	3.1yrs	US$199.11k	0% $ 0
Odysseas Kostas	Independent Director	4.3yrs	US$165.11k	0% $ 0
Athena Papas	Member of C16G2 Clinical Advisory Board	no data	no data	no data
Sarah Schlesinger	Independent Director	4.3yrs	US$167.11k	0% $ 0
Todd Peterson	Independent Director	4.6yrs	US$169.11k	0% $ 0
Robin Kramer	Independent Chairman of the Board	3.4yrs	US$178.11k	0% $ 0
James Bader	Member of C16G2 Clinical Advisory Board	no data	no data	no data
Ann Griffen	Member of C16G2 Clinical Advisory Board	no data	no data	no data
Mark Wolff	Member of C16G2 Clinical Advisory Board	no data	no data	no data
Domenick Zero	Member of C16G2 Clinical Advisory Board	no data	no data	no data

4.3yrs

Average Tenure

63yo

Average Age

Experienced Board: ARMP's board of directors are considered experienced (4.3 years average tenure).

Armata Pharmaceuticals Management

Management criteria checks 1/4

Key information

Recent management updates

Insufficient new directors

Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

Armata Pharmaceuticals, Inc. Announces CFO Changes

Armata Pharmaceuticals, Inc. Announces Deborah L. Birx to Board of Directors

Armata Pharmaceuticals, Inc., Annual General Meeting, Aug 29, 2023

Armata Pharmaceuticals, Inc. Announces Executive Changes

Recent updates

Insufficient new directors

Armata Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

New minor risk - Market cap size

Consensus EPS estimates fall by 52%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

Armata Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 2A Portion of the Phase 1b/2a 'Disarm' Study of Ap-Sa02 in Adults with Bacteremia Due to Staphylococcus Aureus

Armata Pharmaceuticals, Inc. Announces CFO Changes

Consensus revenue estimates decrease by 44%, EPS upgraded

New minor risk - Revenue size

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Armata Pharmaceuticals, Inc. Announces Deborah L. Birx to Board of Directors

Armata Pharmaceuticals, Inc., Annual General Meeting, Aug 29, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Armata Pharmaceuticals, Inc. Announces Executive Changes

Full year 2022 earnings: EPS and revenues miss analyst expectations

Armata Pharmaceuticals, Inc. announced that it has received $30 million in funding from Innoviva Strategic Opportunities LLC

Armata Pharmaceuticals, Inc. announced that it has received $30 million in funding from Innoviva Strategic Opportunities LLC

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

High number of new directors

Price target increased to US$8.00

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Armata Pharmaceuticals, Inc., Annual General Meeting, Nov 16, 2022

Price target increased to US$8.00

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus Aureus

Consensus forecasts updated

High number of new directors

Armata Pharmaceuticals, Inc. announced that it has received $45 million in funding from Innoviva Strategic Opportunities LLC

Armata Pharmaceuticals, Inc. Announces CFO Changes

Consensus forecasts updated

Full year 2021 earnings: EPS misses analyst expectations

Armata Pharmaceuticals, Inc. Announces Clearance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of AP-PA02 in Non-Cystic Fibrosis Bronchiectasis

Price target increased to US$8.00

Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs

Third quarter 2021 earnings released: US$0.22 loss per share (vs US$0.31 loss in 3Q 2020)

Consensus forecasts updated

Price target increased to US$8.00

Consensus revenue estimates fall to US$666.7k

Armata Pharmaceuticals Inc. announced that it has received $20 million in funding from Innoviva, Inc.

Analysts update estimates

New 90-day high: US$5.07

New 90-day low: US$2.83

Earnings beat expectations, revenue disappoints

New 90-day high: US$3.94

Armata Pharmaceuticals Inc. Appoints Mina Pastagia as Vice President of Clinical Development

Armata Pharmaceuticals Announces Clearance of Investigational New Drug (IND) Application to Initiate Phase 1b/2a Clinical Trial of Lead Candidate AP-PA02 in Pseudomonas aeruginosa Infections

New 90-day low - US$3.26

Armata Pharmaceuticals Inc.(AMEX:ARMP) dropped from Russell Microcap Value Index

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age